Pharmacology
MeOPP is anecdotally said to induce significantly less anxiety than similar piperazines, and is usually taken at doses between 120–200 mg. It does not produce prominent stimulant effects, but is instead said to be relaxing, however it is often mixed with stimulant piperazine derivatives such as benzylpiperazine (BZP) for a combined effect. MeOPP has been found ''in vitro'' to inhibit the reuptake and induce theLegal status
New Zealand
Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with a number of other piperazine derivatives into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18, 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1 April 2008. An amnesty for possession and usage of these drugs remained until October 2008, at which point they became completely illegal.United States
MeOPP is not scheduled at the federal level in the United States.21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.Florida
"Methoxyphenylpiperazine" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROLSee also
* Substituted piperazine *Acta Crystallogr. (2020). E76, 1779-1793Fifteen 4-(2-methoxyphenyl)piperazin-1-ium salts containing organic anions: supramolecular assembly in zero, one, two and three dimensions
C. Harish Chinthal, C. N. Kavitha, H. S. Yathirajan, S. Foro, R. S. Rathore and C. Glidewell Acta Crystallogr. (2019). E75, 1494-1506Twelve 4-(4-methoxyphenyl)piperazin-1-ium salts containing organic anions: supramolecular assembly in one, two and three dimensions
H. Kiran Kumar, H. S. Yathirajan, S. Foro and C. GlidewellReferences
External links
* {{DEFAULTSORT:Methoxyphenylpiperazine, para- Serotonin receptor agonists Monoamine releasing agents Designer drugs